Praxis Precision Medicines, Inc.
General ticker "PRAX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Praxis Precision Medicines, Inc. follows the US Stock Market performance with the rate: 34.5%.
Estimated limits based on current volatility of 4.0%: low 179.29$, high 194.14$
Factors to consider:
- Total employees count: 116 (+41.5%) as of 2024
- Top business risk factors: Need for additional capital, Regulatory and compliance, Limited operating history, Marketing and distribution challenges, Strategic risks and growth management
- Current price 113.2% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [29.22$, 89.08$]
- 2025-12-31 to 2026-12-31 estimated range: [14.48$, 47.94$]
Financial Metrics affecting the PRAX estimates:
- Negative: with PPE of -7.4 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -9.70 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 92.20 > 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term PRAX quotes
Long-term PRAX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $2.45MM | $8.55MM |
| Operating Expenses | $214.99MM | $128.82MM | $208.72MM |
| Operating Income | $-214.99MM | $-126.37MM | $-200.16MM |
| Non-Operating Income | $0.96MM | $3.10MM | $17.35MM |
| R&D Expense | $155.04MM | $86.77MM | $152.41MM |
| Income(Loss) | $-214.03MM | $-123.28MM | $-182.82MM |
| Profit(Loss)* | $-214.03MM | $-123.28MM | $-182.82MM |
| Stockholders Equity | $76.11MM | $69.67MM | $445.45MM |
| Assets | $115.13MM | $87.95MM | $483.11MM |
| Operating Cash Flow | $-185.04MM | $-111.14MM | $-131.76MM |
| Capital expenditure | $0.44MM | $0.05MM | $0.00MM |
| Investing Cash Flow | $96.89MM | $38.95MM | $-248.49MM |
| Financing Cash Flow | $10.46MM | $91.87MM | $514.32MM |
| Earnings Per Share** | $-69.65 | $-18.69 | $-10.21 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.